Relmada Therapeutics Inc RLMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 106.67M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.relmada.com
Valuation
|
Metric
|
RLMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.45 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RLMD
|
|---|---|
Quick Ratio | 29.34 |
Current Ratio | 29.52 |
Interest Coverage | — |
Quick Ratio
RLMD
Profitability
|
Metric
|
RLMD
|
|---|---|
Return on Assets (Normalized) | −40.59% |
Return on Equity (Normalized) | −44.16% |
Return on Invested Capital (Normalized) | −47.79% |
Return on Assets
RLMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vR%vy^? | LOCK|&$%j | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?SQ?Dc$ | LOCK|L$b^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|$<?Nhw& | LOCK|<? | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|n>ggPt>^ | LOCK|T$L> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Nn>b<F | LOCK|$^& | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|pHy#?zv | LOCK|Hj%N% | $30B | |||
| Moderna Inc
MRNA
| LOCK|D#b#mr | LOCK|^>V | $25B | |||
| Incyte Corp
INCY
| LOCK|s!p^%$ | LOCK|Cy | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|!B>DrTh | LOCK|p$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&!<%Ww | LOCK|xBX | $16B |
United States